TransCode raises $7.25M in public offering; expects to regain Nasdaq equity compliance

Transcode Therapeutics, Inc.

Priced public offering of 5,942,623 shares (or pre-funded warrants) and warrants for 11,885,246 shares at $1.22/unit.
Gross proceeds of $7.25M; net proceeds for clinical trials of TTX-MC138 and working capital.
Offering closed Jan 22, 2024; warrants exercisable at $1.22, expire in 3.5 years.
Company believes stockholders' equity now above $2.5M; Nasdaq compliance plan submitted and under review.
H.C. Wainwright acted as placement agent; received agent warrants for 356,557 shares at $1.525.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Transcode Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at approximately $7.25 million (effective 2024-01-18).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers named therein
Value: approximately $7.25 million
Effective: 2024-01-18

Exact text from the filing

On January 18, 2024, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-005595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.